EPIC Bio will develop, manufacture and commercialise pandemic influenza vaccines and therapeutics.
EPIC Bio plans to begin clinical manufacturing of a broad spectrum influenza vaccine candidate in 2011 and initiate a clinical trial in 2012.
Emergent BioSolutions chairman and CEO Fuad El-Hibri said that the firm is pleased to enhance its presence in Asia-Pacific with initiatives that help carry out their corporate mission – to protect life.
“First, by broadening the scope of Emergent’s Singapore operations, not only will it continue to make their present and future biodefense products available, but it will also provide support to the company’s ongoing tuberculosis program as well as explore manufacturing and business development opportunities in the region,” El-Hibri said.
“Second, by forming EPIC Bio with TLV, Emergent leverages important technology and product development know how to complement TLL’s research and development efforts in pandemic influenza.”